The study results showed that the primary endpoint (net change in systolic blood pressure from baseline to 18 months) was significantly reduced in the intervention group compared to the control group. Secondary endpoints in t...
The study results showed that the primary endpoint (net change in systolic blood pressure from baseline to 18 months) was significantly reduced in the intervention group compared to the control group. Secondary endpoints in the intervention group, including the proportion of controlled hypertension at ...
The results of this international randomised trial for 2–50-year-old patients with newly diagnosed Ewing sarcoma show that VDC plus IE chemotherapy was more effective than VIDE for both event-free survival and overall survival, with a greater than 99% chance that the regimen is better for both...
Portal hypertension, defined as a pressure gradient between the hepatic and portal vein of 10 mm Hg or greater, promotes development of varices (collateral vessels that shunt portal blood to systemic veins and often result in dilated esophagogastric channels prone to hemorrhage). Disrupted portal fl...
The study results showed that the primary endpoint (net change in systolic blood pressure from baseline to 18 months) was significantly reduced in the intervention group compared to the control group. Secondary endpoints in the intervention group, including the proportion of controlled hypertension at ...
The study results showed that the primary endpoint (net change in systolic blood pressure from baseline to 18 months) was significantly reduced in the intervention group compared to the control group. Secondary endpoints in t...
Panel: Initial laboratory evaluation in patients suspected as having glomerulonephritis 专家组:疑似肾小球肾炎患者的初步实验室评估 The general management of glomerulonephritis includes a low salt (<2 g per day) diet and an optimisation of blood pressure control (the target systolic blood pressure is <...
RESULTS At the time of study termination, 525 patients were randomized in ISABELA 1 and 781 patients in ISABELA 2 (meanage:70.0 [SD,7.2] years in ISABELA 1and69.8 [SD,7.1] years in ISABELA 2;male:82.4%and81.2%, respectively). The trials were terminated early after an independent data an...